Press release -

LUER-JACK APPROVED FOR SALE & MARKETING IN EUROPE (CE mark)

ConceptoMed today announced that the company has received CE Mark approval for the Luer-Jack® syringe, a new and innovative medical syringe. Luer-Jack® is now ready for the European market and other large markets, where the CE mark allows for market entry.

“Receiving the CE mark for Luer-Jack® follows a substantial company effort to safeguard all processes related to putting a Medical Device syringe on the market. The CE mark represents another very important milestone for ConceptoMed. We look forward to shipping the first orders of Luer-Jack® to our distributors. The company is now applying for an FDA approval to open up the vast potential in the US market”, said CEO M.D. Christian Mide.

In September and October 2015, ConceptoMed announced Luer-Jack® distribution agreements for the United Kingdom, Norway and 9 other countries, and are looking forward to announcing new international distribution agreements in the near future.

About Luer-Jack®

Luer-Jack® will become an important contribution in the struggle for improving procedure quality and safety, as well as ensuring aseptic procedures when handling syringes and needles - thus reducing probability of human error during the disconnection. Current syringes and needles on the market are delivered sterile, in very simple packaging - and it is not obvious that the method of opening the package safeguards sterility during actual use in patient treatment.

A key element of the next-generation medical syringe Luer-Jack® is the development away from using two hands during disconnections. Health authorities and medical professionals now have the option of using medical disposables with integrated safety logic - both on the medical device itself, as well as the package design.

Related links

Topics

  • Business enterprise

ConceptoMed AS is a rising Medtech star with innovative product categories, unique patent protected Medtech technology and strong finances. We develop and commercialize smart Medtech solutions for an international market. Excellence through Simplicity! We are brave, curious, dedicated and open-minded. Based in Norway, the team is continuously meeting milestones and expanding its activities for international growth. For more information on the company and career opportunities, see www.conceptomed.com and www.myshieldkids.com. Follow us on MyNewsdesk and LinkedIn.

Luer-Jack® is a registered trademark owned by ConceptoMed AS. The Luer-Jack® technology is widely patent protected throughout the world, currently with granted patents and pending patents from 8 patent families.

Contacts

Christian Mide

Press contact CEO +47 95 100720

Related media

LUER-JACK APPROVED FOR SALE & MARKETING IN EUROPE (CE mark)
  • LUER-JACK APPROVED FOR SALE & MARKETING IN EUROPE (CE mark)
  • License: Media Use
    The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
  • File format: .pdf
Download
  • LUER-JACK APPROVED FOR SALE & MARKETING IN EUROPE (CE mark)
  • License: Media Use
    The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
  • File format: .docx
Download

Related content

The Intervention Centre, Oslo University Hospital – Final Report Luer-Jack®

From June 2014 to July 2015, The Norwegian Research Council (VRI) supported an evaluation research study on Luer-Jack®, a new medical syringe with one-hand disconnection from needles/cannulas and luer type connections. The Intervention Centre of Oslo University Hospital has conducted the study, and the final report was submitted to ConceptoMed today, 1st of September 2015.

ConceptoMed announces Supply Agreement with Becton, Dickinson & Company

ConceptoMed is pleased to announce that it has reached a supply agreement with Becton, Dickinson & Company (BD) – a leading global medical technology company. ConceptoMed will use the different BD syringes in their production of Luer-Jack® - the new generation of medical syringes.

Luer-Jack Lock patent granted - unscrewing with one hand!

The UK Intellectual Property Office granted 2nd of March 2016 the UK patent for Luer-Jack Lock. The patent is the frontrunner for similar filed applications (pending) in all important markets world wide and is a fundamental member of the Luer-Jack patent family, ensuring a very simple one-hand operated release of connections for different fluid transfer applications.

European and Australian Patent Issued for Luer-Jack

On the 31st of August 2016, the European Patent Office issued an official document granting the European patent for Luer-Jack. IP Australia, the Australian Government agency that administers intellectual property (IP) rights and legislation relating to patents, issued an official document granting the Australian patent for Luer-Jack - also on the 31st of August 2016.

ConceptoMed obtains ISO 13485 certification

ConceptoMed is proud to announce that it successfully passed the ISO 13485 quality assurance audit, and was issued the international ISO 13485 certificate by SP, our Notified Body.

Medtech - Private Placement of €9,4 Million in ConceptoMed AS

The Board of Directors of ConceptoMed AS announce the private placement of equity in ConceptoMed AS. Following the share issue, the number of Shareholders in the company amounts to 73 (previously 37). Gross proceeds from the private placement amounts to NOK 89.056.000 (approx. 9,4 MEUR), whereof 25,5 MNOK were subscribed by existing shareholders.